Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.

We first looked for variable mutant allele expression across regions of each tumor to determine if there was a clear trend where non-primary regions had significantly lower expression than primary regions.

also in 19,460 other papers

We next looked for association of mutant allele expression with neoantigenic status, and we found a significant trend in the UBC case where neoantigenic mutations had consistently lower expression across tumor regions than non-neoantigenic mutations ( figure 6A, B ).

also in 9,774 other papers